Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses

Background: There is need for well-tolerated therapies for prostate cancer (PrCa) secondary prevention and to improve response to radiotherapy (RT). The anti-diabetic agent metformin (MET) and the aspirin metabolite salicylate (SAL) are shown to activate AMP-activated protein kinase (AMPK), suppress...

Full description

Bibliographic Details
Main Authors: Evangelia E. Tsakiridis, Lindsay Broadfield, Katarina Marcinko, Olga-Demetra Biziotis, Amr Ali, Bassem Mekhaeil, Elham Ahmadi, Kanwaldeep Singh, Aruz Mesci, Panayiotis G. Zacharidis, Alexander E. Anagnostopoulos, Tobias Berg, Paola Muti, Gregory R. Steinberg, Theodoros Tsakiridis
Format: Article
Language:English
Published: Elsevier 2021-11-01
Series:Translational Oncology
Subjects:
AMPK
Lipogenesis
mTOR
HIF1a
Histone-H3
Xenografts
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523321002011

Similar Items

Similar Items